Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [2] - The company has an exclusive license for AGAMREE® (vamorolone), a dissociative steroid, which is approved for treating Duchenne muscular dystrophy (DMD) in multiple regions including the U.S., EU, UK, China, and Hong Kong [2] Convertible Bond Update - The conversion price for the newly announced convertible bond is set at CHF 13.5446, which represents a 10% premium to the volume-weighted average price (VWAP) of Santhera's shares on 23 September 2025 [6] - The coupon rate for the bond is 7%, indicating a reduction compared to the previous bond [6] - The total principal amount of the convertible bond, including the exchange at parity of the prior bond, is CHF 20.132 million [6]

Convertible Bond Offering - Ether 作为一种支付超过 3% 收益的资产，非常适合用于可转换债券发行 [1] - 以太坊的波动性和收益性使其成为可转换债券的理想选择 [1] - 公司认为以太坊有发行可转换债券的潜力 [1] Capital Strategy - 公司不惜一切代价筹集资金 [1] - 公司不会为了追赶最大的 ETH 金库而做愚蠢的事情 [1] - 公司不会做以后会后悔的事情，而是以聪明的方式进行长期投资 [2]

Core Insights - Fly Play hf. has secured binding, conditional subscription commitments from investors for a convertible bond totaling ISK 2.4 billion, approximately USD 20 million [1] - The financing round includes participation from the company's largest shareholders as well as new Icelandic investors [1] Company Details - The convertible bond issuance is part of Fly Play hf.'s financing strategy to attract both existing and new investors [1] - Further details regarding the plans for the convertible bond are provided in a company announcement [2]